Journals / Turkish Journal of Hematology / 2011 / Cilt: 28 - Sayı: 3

Topikal Ankaferd® hemostatın büyük arter yaralanmalarında artmış arter içi basınç ile ilişkili cerrahi ve histopatolojik etkileri

Surgical and histopathological effects of topical Ankaferd® hemostat on major arterial vessel injury related to elevated intra-arterial blood pressure

Pages
206–212
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings will inform the design of future experimental and clinical studies on the anti-bleeding and vascular repairing effects of the novel hemostatic agent ABS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to assess the surgical and histopathological hemostatic effects of topical Ankaferd blood stopper (ABS) on major arterial vessel injury related to elevated intra-arterial blood pressure in an experimental rabbit model.
📊
Key Findings & Data:Materials and Methods: The study included 14 New Zealand rabbits.
💡
Conclusion & Impact:These findings will inform the design of future experimental and clinical studies on the anti-bleeding and vascular repairing effects of the novel hemostatic agent ABS.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to assess the surgical and histopathological hemostatic effects of topical Ankaferd blood stopper (ABS) on major arterial vessel injury related to elevated intra-arterial blood pressure in an experimental rabbit model. Materials and Methods: The study included 14 New Zealand rabbits. ABS was used to treat femoral artery puncture on 1 side in each animal and the other untreated side served as the control. Likewise, for abdominal aortic puncture, only 50% of the aortic injuries received topical liquid ABS and the oth- ers did not (control). The experiment was performed under conditions of normal arterial blood pres- sure and was repeated with a 50% increase in blood pressure. Histopathological analysis was per- formed in all of the studied animals. Results: Mean bleeding time in the control femoral arteries was 105.0±18.3 s, versus 51.4±9.8 s (p<0.05) in those treated with ABS. Mean blood loss from the punctured control femoral arteries was 5.0±1.5 mg and 1.6±0.4 mg from those treated with ABS (p<0.05). Histopathological examination of the damaged arterial structures showed that ABS induced red blood cell aggregates. Conclusion: ABS administered to experimental major arterial vessel injury reduced both bleeding time and blood loss under conditions of normal and elevated intra-arterial blood pressure. ABS-induced erythroid aggregation was prominent at the vascular tissue level. These findings will inform the design of future experimental and clinical studies on the anti-bleeding and vascular repairing effects of the novel hemostatic agent ABS.

Özet

Amaç: Bu çalışmanın amacı büyük arter yaralanmalarında arter içi basınç artışı ile paralel olarak uygulanan topikal Ankaferd Blood Stopper (ABS)’ın cerrahi ve histopatolojik hemostatik etkilerini deneysel bir tavşan modelinde değerlendirmektir. Yöntemler ve Gereçler: Çalışma grubunu ondört Yeni Zelanda tavşanı oluşturmuştur. Hayvanların bir ekstremitesinde oluşturulan femoral arter hasarında ABS uygulanırken karşı ekstremite kontrol olarak kullanılmıştır. Benzer biçimde, abdominal aort hasarı oluşturulan hayvanlarda, hayvanların yarısında topikal ABS uygulanırken diğer grup kontrol olarak çalışmaya alınmıştır. Büyük arter kanamaları normal arteriyel basınç altında oluşturulmuşken, çalışma intra-arteriyel basınç %50 arttırılarak tekrar edilmiştir. Histopatholojik incelemeler çalışılan tüm hayvanlarda gerçekleştirilmiştir. Bulgular: Hasar görmüş femoral arterden gelişen ortalama ‘kanama zamanı’ ABS olmadan 105.0±18.3 sn. iken topikal ABS uygulamasıyla 51.4±9.8 saniyeye düşürülmüştür (p<0.05). Hasar görmüş femo- ral arterden gelişen ortalama ‘kanama miktarı’ ABS olmadan 5.0±1.5 mg iken topikal ABS uygulamasıyla 1.6±0.4 mg’a gerilemiştir (p<0.05). Abdominal aorta kanama modelinde ise ortalama ‘kanama zamanı’ ve ortalama ‘kanama miktarı’ kan basıncı yükseltildiğinde bile ABS kullanımıyla azalmasına karşın kontrol grupları ile farklılık istatistiksel anlamlılık düzeylerine erişmemiştir. Hasar görmüş arteriyel yapıların histopatolojik incelemelerinde ABS uygulaması ile ilişkili kırmızı küre aggregatları belirgin biçimde gözlenmiştir. Sonuç: Topikal Ankaferd Hemostat uygulaması deneysel büyük arter modelinde “kanama zamanı” ve “kanama miktarı” değerlerini normal ve yüksek arter-içi basınç durumlarında aşağıya çekmiştir. ABS- bağımlı eritroid aggregasyon vasküler doku düzeyinde belirgin olarak gösterilmiştir. Gözlemler bu yeni hemostatik ajan’ın kanamayı engelleyici ve damar onarımına zemin hazırlayan etkilerinin gelecek deneysel ve klinik çalışmalarla ortaya konulması için temel teşkil etmektedir.

🔖

Cite This Article

ULUS, A. T., TURAN, N. N., ÖZYALÇIN, S., AYDOĞ, G., ULUS, F., GÖKER, H., HAZNEDAROĞLU, C. İ. (2011). Topikal Ankaferd® hemostatın büyük arter yaralanmalarında artmış arter içi basınç ile ilişkili cerrahi ve histopatolojik etkileri. Turkish Journal of Hematology, Cilt: 28 - Sayı: 3, 206–212. https://ajindex.com/articles/412695

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Haznedaroglu BZ, Haznedaroglu IC, Walker SL, et al. Ultrastructural and Morphological Analyses of the In Vitro and In Vivo Hemostatic Effects of Ankaferd Blood Stopper. Clinical and Applied Thrombosis-Hemostasis 2010;16:446-53
  2. Haznedaroglu IC. Time to take a healthier view of his- tory. Nature 1998;396:108
  3. Goker H, Haznedaroglu IC, Ercetin S, et al. Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. Journal of International Medical Research 2008;36:163-70
  4. Al B, Yildirim C, Cavdar M, et al. Effectiveness of Ankaferd blood stopper in the topical control of active bleeding due to cutaneous-subcutaneous incisions. Saudi Medical Journal 2009;30:1520-5
  5. Arslan S, Haznedaroglu IC, Oz B, et al. Endobronchial application of Ankaferd blood stopper to control pro- fuse lung bleeding leading to hypoxemia and hemodynamic instability. Respiratory Medicine 2008;doi:10.1016/j.rmedc.2008.10.016 6. Balcik OS, Koroglu M, Cipil H, Kaftan O, Maral, S, Gurel A, Goker H, Haznedaroglu I, C Kosar, A. A Placebo- Controlled, Randomized, Double-Blinded, Cross-Over Phase I Clinical Study to Demonstrate Safety of Ankaferd Blood Stopper Topical Usage In Healthy Volunteers. Int J Lab Hem 2010;32:126-7
  6. Baykul T, Alanoglu EG, Kocer G. Use of Ankaferd Blood Stopper as a hemostatic agent: a clinical experience. J Contemp Dent Pract 2010;11:E088-94
  7. Kurt M, Akdogan M, Ibis M, Haznedaroglu IC. Ankaferd blood stopper for gastrointestinal bleeding. Journal of Investigative Surgery 2010;23:239
  8. Kurt M, Oztas E, Kuran S, Onal IK, Kekilli M, Haznedaroglu IC. Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability. Am J Emerg Med 2009;27:631 e1-2
  9. Meric Teker A, Korkut AY, Kahya V, et al. Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis. Eur Arch Otorhinolaryngol 2010;267:1377-81
  10. Oner A, Dogan M, Kaya A, et al. New Coagulant Agent (Ankaferd Blood Stopper) for Open Hemorrhages in Hemophilia With Inhibitor. Clin Appl Thromb Hemost 2009
  11. Teker AM, Korkut AY, Gedikli O, et al. Prospective, con- trolled clinical trial of Ankaferd Blood Stopper in chil- dren undergoing tonsillectomy. International Journal of Pediatric Otorhinolaryngology 2009;73:1742-5
  12. Teker AM, Korkut AY, Kahya V, et al. Prospective, ran- domized, controlled clinical trial of Ankaferd Blood Stopper in patients w